氧化应激相关基因的遗传突变可预测原发性乳腺癌的化疗耐药:一项前瞻性观察性研究和验证

Genetic variants in oxidative stress-related genes predict chemoresistance in primary breast cancer: A prospective observational study and validation
2012-07-13 09:14点击:106次发表评论
作者:Yu, K.-D.a, Huang, A.-J.a, Fan, L.a, Li, W.-F.b, S
机构: 复旦大学上海医学院附属肿瘤医院乳腺外科
期刊: CANCER-AM CANCER SOC2012年1月2期72卷

Department of Breast Surgery, Shanghai Medical College, Fudan University, 399 Ling-Ling Road, Shanghai 200032, China

Chemotherapy response in patients with primary breast cancer is difficult to predict and the role of host genetic factors has not been thoroughly investigated. We hypothesized that polymorphisms in oxidative stress (OS)-related genes, including estrogen-quinone metabolizing enzymes NQO2 and GSTM1-5, may influence disease progression and treatment response. In this prospective observational study, nineteen polymorphisms tagging known variations in candidate genes were genotyped and analyzed in 806 patients with primary breast cancer. Three functional polymorphisms, which were shown to affect gene expression levels in experiments in vitro and ex vivo, modified the effect of chemotherapy on disease-free survival. There were significant interactions between chemotherapy and individual polymorphisms or combined genotypes (designated as genetic score). Patients harboring high genetic score had a 75% reduction in the hazard of disease progression compared with patients with low genetic score when no chemotherapy was administered (HR = 0.25, 95% CI: 0.10-0.63, P = 0.005); however, they received much less survival benefit from adjuvant chemotherapy compared with patients with low genetic score when chemotherapy was administered (HR = 4.60 for interaction, 95% CI: 1.63-13.3, P = 0.004). These findings were validated in another population (n = 339). In conclusion, germline polymorphisms in OS-related genes affect chemotherapy sensitivity in breast cancer patients. Although reduced OS levels might prevent breast cancer progression, they probably compromise the effectiveness of adjuvant chemotherapy. Our findings also indicate that host-related factors must be considered for individualized chemotherapy. ©2011 AACR.

Shao, Z.-M.; Department of Breast Surgery, Shanghai Medical College, Fudan University, 399 Ling-Ling Road, Shanghai 200032, China; email: zhimingshao@yahoo.com

通讯作者:Shao, Z.-M.; Department of Breast Surgery, Shanghai Medical College, Fudan University, 399 Ling-Ling Road, Shanghai 200032, China; email: zhimingshao@yahoo.com
学科代码:肿瘤学   关键词:氧化应激相关基因的遗传突变可预测原发性乳腺癌的化疗耐药:一项
来源: Scopus
Scopus介绍:Scopus 于2004年11月正式推出,是目前全球规模最大的文摘和引文数据库。Scopus涵盖了由5000多家出版商出版发行的科技、医学和社会科学方面的18,000多种期刊,其中同行评审期刊16,500多种。相对于其他单一的文摘索引数据库而言,Scopus的内容更加全面,学科更加广泛,特别是在获取欧洲及亚太地区的文献方面,用户可检索出更多的文献数量。通过Scopus,用户可以检索到1823年以来的近4000万条摘要和题录信息,以及1996年以来所引用的参考文献。数据每日更新。 马上访问Scopus网站http://www.scopus.com/
顶一下(0
您可能感兴趣的文章
    发表评论网友评论(0)
      发表评论
      登录后方可发表评论,点击此处登录